AGE Stock Overview
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
AgeX Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.10 |
| 52 Week High | US$35.17 |
| 52 Week Low | US$10.90 |
| Beta | 1.19 |
| 1 Month Change | -14.70% |
| 3 Month Change | -23.49% |
| 1 Year Change | -48.68% |
| 3 Year Change | -80.64% |
| 5 Year Change | -92.39% |
| Change since IPO | -88.35% |
Recent News & Updates
Shareholder Returns
| AGE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -23.6% | 2.6% | 2.8% |
| 1Y | -48.7% | -3.3% | 24.6% |
Return vs Industry: AGE underperformed the US Biotechs industry which returned 10.2% over the past year.
Return vs Market: AGE underperformed the US Market which returned 29.8% over the past year.
Price Volatility
| AGE volatility | |
|---|---|
| AGE Average Weekly Movement | 18.5% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AGE's share price has been volatile over the past 3 months.
Volatility Over Time: AGE's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 6 | Joanne Hackett | www.agexinc.com |
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company’s lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology.
AgeX Therapeutics, Inc. Fundamentals Summary
| AGE fundamental statistics | |
|---|---|
| Market cap | US$31.51m |
| Earnings (TTM) | -US$14.80m |
| Revenue (TTM) | US$142.00k |
195.5x
P/S Ratio-1.9x
P/E RatioIs AGE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AGE income statement (TTM) | |
|---|---|
| Revenue | US$142.00k |
| Cost of Revenue | US$40.00k |
| Gross Profit | US$102.00k |
| Other Expenses | US$14.91m |
| Earnings | -US$14.80m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.92 |
| Gross Margin | 71.83% |
| Net Profit Margin | -10,424.65% |
| Debt/Equity Ratio | 81.5% |
How did AGE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/03/26 12:18 |
| End of Day Share Price | 2024/03/26 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
AgeX Therapeutics, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|